key: cord-0921293-yv7v1su7
authors: Egwang, Thomas G.; Owalla, Tonny Jimmy; Okurut, Emmanuel; Apungia, Gonzaga; Fox, Alisa; De Carlo, Claire; Powell, Rebecca L.
title: Differential pre-pandemic breast milk IgA reactivity against SARS-CoV-2 and circulating human coronaviruses in Ugandan and American mothers
date: 2021-09-20
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.09.039
sha: e91d14042e9887423509d61af481dc941fd512eb
doc_id: 921293
cord_uid: yv7v1su7

Objective Uganda has registered fewer COVID-19 cases and deaths per capita than Western countries. Lower numbers of cases and deaths might be due to pre-existing cross-immunity induced by circulating common cold human coronaviruses (HCoVs) before the COVID-19 pandemic. To investigate pre-existing mucosal antibodies against COVID-19, we compared IgA reactivity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and HCoVs in milk of mothers collected in 2018. Methods Ugandan and US milk samples were run on enzyme-linked immunoadsorbent assay (ELISA) to measure specific IgA to SARS-CoV-2 and HCoVs NL63, OC43, HKU1, and 229E spike proteins. Pooled plasma from US COVID-19 positive and negative cases were positive and negative controls, respectively. Results One Ugandan mother had high milk IgA reactivity against all HCoVs and SARS-CoV-2 spike proteins. Ugandan mothers had significantly higher IgA reactivity against the betacoronavirus HCoV-OC43 than US mothers (p = 0.018). By contrast, US mo thers had significantly higher IgA reactivity against the alphacoronaviruses HCoV-229E and HCoV-NL63 than Ugandan mothers (p < 0.0001 and 0.035, respectively). Conclusion Some Ugandan mothers have pre-existing HCoV-induced IgA antibodies against SARS-CoV-2 which may be passed to infants via breastfeeding.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide causing > 177,100,000 coronavirus disease 2019 cases by June 18, 2021 (World Health Organization, 2021 . Uganda, like other African countries, has registered fewer COVID-19 cases and deaths per capita than non-African countries (World Health Organization, 2021) . The lower numbers of cases and deaths in Africa by comparison with those in Western countries might be partly due to cross-immunity induced by circulating common cold human corona viruses (HCoVs) (Doshi, 2020) . The HCoVs 229E, NL63, OC43 and HKU1 share high sequence similarity with SARS-CoV-2 proteins [Kaur et al., 2020] , cause mild upper respiratory tract infections (common cold) (van der Hoek, 2007) , and induce cross-reacting antibodies and T cells to SARS-CoV-2 in people never exposed to SARS-CoV-2 (Ng et al., 2020; Saletti et al., 2020) . HCoV-induced antibodies with SARS-CoV-2 neutralizing activity targeting the S2 subunit of the SARS-CoV-2 Spike protein have been found to be present in pre-pandemic samples of 21/48 (44 %) children and 16/302 (5.3%) adults from the UK never exposed to SARS-CoV-2 (Ng et al., 2020) . A Dutch study similarly demonstrated pre-existing HCoV-specific T cells in young but not older adults (Saletti et al., 2020) . Notably, the prevalence of HCoV-induced cross-reactive antibodies in prepandemic sub-Saharan African sera was 6-8-fold higher compared with US pre-pandemic sera (Tso et al., 2020) . These findings support the premise that systemic cross-immunity induced by HCoVs partly explains the lower numbers of COVID-19 cases and deaths in younger individuals in general and in Africa as a geographic region. However, there is a paucity of studies on pre-existing cross-reactive mucosal immunity against SARS-CoV-2.

Mucosal immunity is predominantly effected by IgA and secretory IgA (IgA/sIgA) and IgM/sIgM at mucosal surfaces such as the gastrointestinal and reproductive tracts, lungs, tears, saliva and breast milk (Brandtzaeg et al., 2010) . There is increasing evidence of a robust mucosal immunity against SARS-CoV-2 (Russell et al., 2020) . IgA antibody responses to SARS-CoV-2 have been reported in nasal fluids, tears, and saliva while elevated IgA-secreting plasmablasts expressing the mucosal chemokine receptor CCR10 were reported in peripheral blood of SARS-CoV-2-infected subjects (Isho et al., 2020; Cervia et al.,2020; Sterlin et al., 2021) . CCR10 and its ligand CCL28 are uniquely involved in mucosal immunity (Xiong et al., 2012; Morteau et al., 2008) . Breast milk provides a unique window on mucosal immunity in mothers and provides protection against a legion of pathogens in infants (Le Doare et al., 2018) . There is evidence that IgA antibodies are robustly induced by natural SARS-CoV-2 and human coronavirus infections and various COVID-19 vaccines. First, several studies demonstrated IgA antibodies against SARS-CoV-2 with virus neutralizing activity in breast milk of mothers with COVID-19 [Pace et al., 2021; Fox et al., 2020a] . The reported breast milk antibody isotypes included IgA/secretory IgA(IgA/sIgA), IgM/sIgM, and IgG with IgA being the predominant antibody (Pace et al., 2021; Fox et al., 2020a; Zhu et al., 2021) . Second, COVID-19 vaccination has been rolled out in several countries and recent published reports indicate that vaccination induces robust IgA and IgG antibody responses with neutralizing activity in breast milk which may confer protection to breastfeeding infants (Collier et al., 2021; Perl et al., 2021; Shlomai et al., 2021; Gray et al., 2021) . Finally, experimental infection with HCoV-229E induced protective IgA antibodies which reduced virus shedding in human volunteers (Callow, 1985) .

The current limited access to COVID-19 vaccines in Africa leaves millions of mothers and their infants vulnerable to SARS-CoV-2 infection and COVID-19 related illnesses. Protection for these mother-infant pairs may therefore depend in the interim on pre-existing cross-reactive mucosal immunity acquired by mothers before the pandemic. There is a dearth of information about pre-existing crossreactive mucosal immunity induced by HCoVs. Two US studies reported the presence of cross-reactive breast milk antibodies against HCoVs in US pre-pandemic breast milk samples which recognize SARS-CoV-2 (Pace et al., 2021; Demers-Mathieu et al., 2021b R1) . Pre-existing immunity in breastfeeding mothers might provide temporary protection against severe COVID-19 illness (Sagar et al., 2021) or reduce COVID-19 symptom duration (Gouma et al., 2021) in mother-infant dyads with no immediate access to COVID-19 vaccines. This is particularly relevant to sub-Saharan African countries where COVID-19 vaccination roll out is expected to be slow due to limited vaccine supplies and vaccine hesitancy must be overcome (Wirsiy et al., 2021) . To the best of our knowledge, no study has investigated the presence of cross-reactive IgA antibodies against the S proteins of SARS-CoV-2 and HCoVs in pre-pandemic breast milk samples collected in Africa prior to 2019. In this study, we tested the hypothesis that breastfeeding rural Ugandan mothers who have never been exposed to SARS-CoV-2 have pre-existing cross-reactive IgA antibodies induced by endemic HCoVs which might be passed to infants via breast milk. We therefore measured IgA antibodies against the S proteins of SARS-CoV-2 and the four HCoVs 229E, NL63, OC43 and HKU1 in pre-pandemic Ugandan milk samples collected in March 2018 before the emergence of the COVID-19 pandemic. We also compared IgA antibody responses in pre-pandemic Ugandan and US breast milk samples to gauge differences in pre-existing cross-reactive mucosal immunity between the two study populations before the pandemic. Our findings support the hypothesis that breastfeeding Ugandan mothers who have never been exposed to SARS-CoV-2 may have pre-existing HCoV-induced IgA antibodies in milk which might be transferred to infants via breastfeeding.

A cross-sectional study examining various breast milk parameters in a cohort of breastfeeding mother-infant dyads was undertaken in March 2018. The study was part of a larger malaria study that was reviewed and approved by the Research Ethics Committee of the Vector Control Division, Ministry of Health and the Uganda National Council for Science and Technology. The study was conducted at the Med Biotech Laboratories research clinic at St. Anne Health Center III in Usuk Subcounty, Katakwi District, in Northeastern Uganda. The study population comprised of mothers with a mean age of 26 (range 6-40) years who were breastfeeding at the time of the study. Inclusion criteria were: (1) willingness to donate breast milk; (2) age 18 and above. The sole exclusion criterion was clinical suspicion or evidence of mastitis in one or both breasts. Details about these mothers have been previously published (Owalla et al., 2020) . USA samples were collected in 2018-2019 in New York, NY from healthy women having a mean age of 34 (range 21-44) years as part of studies related to influenza and HIV under approved Ichan School of Medicine at Mount Sinai IRB protocols. All donors provided written informed consent.

For Ugandan samples, breast milk was manually collected with the assistance of a lactation nurse as described (Slusher et al., 2012) . Briefly, the skin around the areola and nipple was cleaned with an alcohol swab, the breast gently massaged, and 5-mL milk samples were manually expressed into 50-mL Falcon tubes which were immediately plunged into dry ice. Milk samples were transported to the lab in Kampala where they were aliquoted and stored at -20 ºC until shipped on dry ice to the USA. For American samples, participants were asked to collect milk into a clean container using electronic or manual pumps at home. Milk was frozen in participants' home freezers until samples were picked up by researchers and transferred on ice to the Mount Sinai Hospital where they were stored at -80°C until testing.

To examine the levels of SARS-CoV-2 and HCoV Abs in human milk, we modified an ELISA that was recently developed and validated for use in blood serum/plasma Stadlbauer et al., 2020) and have been successfully adapted this assay for use with human milk (Fox et al., 2020) . The antigens were Spike protein of SARS-CoV-2 and the S1 domain of HCoV-HKU1, HCoV-OC43, HCoV-229E, and HCoV-NL63. SARS-CoV-2 Spike protein was prepared as described (Stadlbauer et al., 2020) . HCoV antigens were purchased from SinoBiologicals Company and the details of their preparations are described in detail on the company website (https://www.sinobiological.com/recombinant-proteins/hcov-oc43-cov-spike-40607-v08h1; https://www.sinobiological.com/recombinant-proteins/hcov-hku1-cov-spike-40021-v08h; https://www.sinobiological.com/recombinant-proteins/hcov-nl63-cov-spike-40600-v08h; https://www.sinobiological.com/recombinant-proteins/hcov-229e-cov-spike-40601-v08h).

The recombinant antigens were His-tagged and purified to homogeneity as confirmed by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). The recombinant antigens were diluted in phosphate buffered saline (PBS), coated onto microtiter plates overnight at 4°C at a concentration of 50 ng /well, and used within 24 hours. Briefly, before Ab testing, milk samples were thawed, centrifuged at 800g for 15 min at room temperature, fat was removed, and supernatant transferred to a new tube. Centrifugation was repeated 2x to ensure removal of all cells and fat. Skimmed acellular milk was aliquoted and frozen at -80°C until testing. Both

Ugandan and US pre-pandemic milk samples were tested in duplicate, measuring IgA against the full trimeric Spike protein of SARS-CoV-2, or the S1 domain of HCoV-HKU1, HCoV-OC43, HCoV-229E, or HCoV-NL63. Due to the limited availability of Ugandan samples, milk was used diluted 1 in 10 and titrated 2.5-fold in 1% bovine serum albumin (BSA)/PBS and added to the plate. Negative controls were wells without antigen, secondary antibody, nor milk. We also employed pooled milk or sera from SARS-CoV-2-positive or negative cases as positive and negative controls for assay-to-assay consistency. Plates were incubated at 4°C overnight, washed in 0.1% Tween 20/PBS (PBS-T), and blocked in PBS/3% goat serum/0.5% milk powder/3.5%

PBS-T for 1h at room temperature. After 2h incubation at room temperature, plates were washed and incubated for 1h at room temperature with horseradish peroxidase-conjugated goat antihuman-IgA (Rockland) diluted in 1% BSA/PBS. Plates were developed with 3,3',5,5'-Tetramethylbenzidine (TMB) reagent followed by 2N hydrochloric acid (HCl) and read at 450nm on a BioTek Powerwave HT plate reader.

Endpoint dilution titers were determined from log-transformed titration curves using 4-parameter non-linear regression and an OD cutoff value of 1.0. Endpoint dilution positive cutoff values were determined as above. Mann-Whitney U tests were used to determine if the grouped Ugandan and American pre-pandemic milk samples differed in terms of specific reactivity to a given antigen. Pearson correlation tests were performed to compare SARS-CoV-2 and HCoV reactivity. We performed an outlier analysis using Grubbs' test. All statistical tests were performed in GraphPad Prism, were 2-tailed, and significance level was set at p-values < 0.05.

Pre-pandemic Ugandan and American milk samples (N=25 per group) were assayed in duplicate by ELISA in order to compare the levels of IgA antibody reactivity to the Spike protein. was not significant, as the outlier Ugandan high responder sample strongly influenced the higher mean ( Fig. 1F ).

Milk samples were assayed against the HCoVs as described above. The Ugandan high-responder noted for SARS-CoV-2 was also highly reactive against both alphacoronaviruses (Fig. 1) p=0.0003; Fig. 1G ). Statistical significance of the difference was increased if the Ugandan highresponder was removed from the dataset (p<0.0001; Fig. 1G , right panel). Against HCoV-NL63, endpoint titers were not significantly different if the Ugandan high responder was included in the data;

however, if this outlier was removed, endpoint titers were also significantly lower for the Ugandan samples (Ugandan mean endpoint titer=18.2; American mean endpoint titer=41.4; p=0.035; Fig. 1H ).

The Ugandan high-responder noted for SARS-CoV-2 was also highly reactive against both betacoronaviruses (Fig. 1) . Against the HKU1 Spike, IgA reactivity was highly similar at 1/10 dilution between the Ugandan and American sample groups (Ugandan mean OD=2.16, American mean OD=2.26; p=NS; Fig. 1D and data not shown). Endpoint titers were also not significantly different, though the Ugandan mean was increased due to the robust response of the Ugandan high responder (Ugandan mean endpoint titer=162; American mean endpoint titer=107; p=NS). Against HCoV-OC43, initially it was evident that a subset of Ugandan samples exhibited increased reactivity, though comparing the 2 groups on the whole did not yield significant differences (data not shown); therefore, 30

additional Ugandan and 27 additional American samples were analyzed to determine if the observed trend of higher reactivity might become significant. It was found for milk at 1/10 dilution that Ugandan samples exhibited significantly higher IgA reactivity against HCoV-OC43 (Ugandan mean OD=1.76, American mean OD=1.37; p=0.0132; Fig. 1E and data not shown). Endpoint titers were also significantly higher for the Ugandan samples (Ugandan mean endpoint titer=82; American mean endpoint titer=28.3; p=0.0182; Fig. 1J ). The higher reactivity of the Ugandan samples remained significant even with the removal of the high-responder from the dataset (p=0.0258; Fig.1J ).

Correlation analyses were performed to determine the relationship between pre-pandemic HCoV and SARS-CoV-2 IgA reactivity for each group of milk samples. For the Ugandan milk samples, a significant positive correlation was found for reactivity against each HCoV compared to SARS-CoV-2 ( Fig. 2A; p<0 .0001). However, if the Ugandan high responder sample was removed from the dataset, these correlations were no longer evident (data not shown). No correlation between HCoV and SARS-CoV-2 IgA reactivity was found for the American samples (Fig. 2B ).

African countries have registered fewer COVID-19 cases and deaths per capita than the US and other Western countries (WHO, 2021). The lower numbers of cases and deaths might be partly due to cross-immunity induced by circulating common cold HCoVs which share high sequence similarity with SARS-CoV-2 proteins (Kaur et al. 2020) and induce cross-reacting antibodies and T cells to SARS-CoV-2 in people never exposed to SARS-CoV-2 (Nga et al., 2020; Saletti et al., 2020) . There is a paucity of studies on pre-pandemic breast milk antibodies against SARS-CoV-2 and HCoVs in African mothers.

The rationale for our research focus on breast milk is because it is reflective of the common mucosal immune system and therefore relevant in terms of mucosal antibodies against COVID-19 in both adults and infants. Here we report for the first time that pre-pandemic breast milk samples obtained from rural Ugandan mothers in 2018 contain IgA antibodies that are reactive to the Spike proteins of all four HCoVs tested with low-to-moderate cross-reactivity to SARS-CoV-2. In comparing these data to those of pre-endemic US samples, it was evident that there is a considerable unique IgA reactivity profile in Ugandan and US mothers for most of the HCoVs tested that is likely geographically-based.

Ugandan mothers had significantly higher levels of milk IgA antibodies against HCoV-OC43 by comparison with US mothers. There was also a higher prevalence of milk IgA antibodies against HCoV OC43 in Ugandan mothers by comparison with US mothers (71 % versus 55 %). By contrast, US mothers had significantly higher levels and prevalence of milk IgA antibodies against the alphacoronaviruses HCoV NL63 and HCoV 229E. Younger individuals have a higher prevalence of preexisting humoral and T cell immunity-induced by HCoVs (Ng et al., 2020; Saletti et al. 2020) . It is unlikely that the observed differences in IgA reactivity in our study populations were due to age differences between Ugandan (mean age 26 years) and US mothers (mean age 34). The differential breast milk IgA reactivity against HCoVs in Ugandan and US mothers could be due to differences in the distribution of alpha-and betacoronaviruses in the two study populations. Our data indicate that there is a higher prevalence of HCoV OC43 in the Ugandan study population. A recent hospital-based study of Ugandan patients with influenza-like illness demonstrated a high seroprevalence of HCoVs but used a nucleoprotein-based ELISA which could not distinguish between different species of HCoVs (Mulabbi et al., 2021) . Molecular surveillance and seroprevalence studies in Kenya and Ghana, respectively, demonstrated the predominance of HCoV OC43 among HCoVs (Sipulwa et al., 2016; Owusu et al., 2021) . These previous studies and our own underscore the potential public health significance of certain HCoVs, especially OC43, in Africa in the context of pre-existing cross-reactive IgA against SARS-CoV-

clinical outcomes of COVID-19 patients in Africa.

Over one third of Ugandan breastfeeding mothers exhibited pre-pandemic milk IgA reactivity against SARS-CoV-2 and over 70 % exhibited pre-pandemic milk IgA reactivity against HCoV-OC43. Pre-existing HCoV-OC43-induced cross-reactive mucosal antibodies might provide moderate protection against COVID-19 in rural Ugandans including mothers and infants. This premise is supported by several published studies. First, recent endemic HCoV infections are associated with a reduced severity of COVID-19 and risk of admission to the intensive care unit (Sagar et al., 2021) and reduced COVID-19 symptom duration (Gouma 2021 (Gouma et al., 2021 . Second, previous viral symptoms correlated with the level and duration of crossreactive antibodies to S1 and S2 subunits of SARS-CoV-2 and HCoV-OC43 in breast milk (Demers-Matthieu et al., 2021b) . Third, higher antibody levels against HCoV-OC43 S protein were seen in individuals with pre-pandemic SARS-CoV-2 reactive antibodies than in those without . Additionally, HCoV-OC43 immunity may impact the crossreactive response in ways not measured in the present study, including an enhanced memory B cell population and/or reactive T cells. It also remains to be established how Ugandan milk IgA reactivity against HCoV-OC43 relates to mucosal immunity in other mucosal compartments such as the lungs which are most affected by severe COVID-19 disease.

There is also a growing body of evidence that cross-reactive antibodies induced by betacoronaviruses may be associated with severe and fatal COVID-19 illness. First, SARS-CoV-2 infection boosts antibodies against betacoronaviruses (Anderson et al., Nguyen-Contant et al., 2020; Shrock et al., 2020) probably due to the original antigenic sin. Original antigenic sin occurs when a prior immune response compromises de novo responses to a closely related pathogen, variant or serotype and has been well-characterized in influenza virus and dengue infections (Francis 1960; Mongvolsapaya et al. 2003; Linderman et al., 2014) . Second, SARS-CoV-2 back-boosting of antibodies to shared epitopes in the S2 subunits of SARS-CoV-2 and betacoronaviruses is accompanied by weaker and delayed de novo antibody responses to SARS-CoV-2 in severe and fatal COVID-19 cases (Westerhuis et al. 2021; McNaughton et al., 2021) .

In our study, US pre-pandemic samples exhibited significantly more milk IgA reactivity to

HCoV-229E and HCoV-NL63 compared to Ugandan samples. It is therefore possible that this enhanced antibody responses to alphacoronaviruses is accompanied by weaker and delayed antibodies to SARS-CoV-2 in US mothers. It is also plausible that the strong antibody responses seen in Ugandan mothers against HCoV-OC43 may skew antibody responses against SARS-CoV-2. Suboptimal antibody responses can result in antibody dependent enhancement of infection and antibody-mediated immune enhancement with poor outcomes (Iwasaki and Yang, 2020) . Prospective studies in mothers with COVID-19 illness are required to establish whether increased HCoV OC43-induced IgA responses are associated with poor clinical outcomes.

One Ugandan mother had high milk IgA reactivity against the spike proteins of SARS-CoV-2 and all four HCoVS. The high reactivity to SARS-CoV-2 was not seen in milk samples from other mothers from the same village. It is not clear whether the robust cross-reactive IgA response in this mother could be due to a previous unique exposure to a zoonotic coronavirus circulating in this region that is highly related to SARS-CoV-2. Indeed, molecular surveillance in East Africa has identified bat coronaviruses which are relatives of the HCoVs Middle East respiratory syndrome coronavirus (MERS-CoV), NL63 and 229E (Anthony et al., 2017; Tao et al., 2017) . A significant correlation was present between breast milk IgA reactivity to SARS-CoV-2 and all 4 HCoVs only when the Ugandan high responder mother was included. The correlation was not significant when this outlier was excluded. We do not have enough milk sample remaining from the outlier mother to undertake further studies to confirm immunologic cross-reactivity with SARS-CoV-2 through competition ELISA. We are undertaking further investigations to establish whether there are more Ugandan breastfeeding mothers with such potent milk cross-reactive IgA against SARS-CoV-2 for further studies.

Our study has several limitations. First, only a small number of pre-pandemic breast milk samples were analyzed for IgA reactivity. It is therefore not possible to conclude whether the general population of Ugandan breastfeeding mothers have similar cross-reactive IgA antibodies.

Second, due to the limited amounts of milk samples, we were not able to undertake SARS-CoV-2 neutralization studies to determine the functional relevance of the highly reactive IgA antibodies in some pre-pandemic Ugandan milk samples. However, we have previously reported that breast milk IgA titers correlate with virus neutralization activity in US mothers (Fox et al., 2021b) . Furthermore, for the same reasons, we did not carry out competition ELISA with SARS-CoV-2 Spike protein using Ugandan samples. There are plans to identify Ugandan pre-pandemic milk samples with high IgA reactivity and undertake neutralization and competition experiments to establish their functional relevance to protection and target specificity. Third, the crosssectional design of the study precluded the generation of hypotheses about cause-effect relationships. The design was inevitable because samples were collected at a single time point before the COVID-19 pandemic. Fourth, the study only looked at IgA reactivity and did not investigate other antibody isotypes that may be relevant to humoral mucosal cross-immunity against COVID-19. Finally, the study did not correlate breast milk and serum antibody reactivity to establish the relationship between systemic and mucosal cross-reactive antibodies to SARS-CoV-2 and HCoVs in the study region. Some of these limitations will be addressed in a future study with a larger number of Ugandan pre-pandemic breast milk samples.

In conclusion, our preliminary findings support the premise that HCoV-induced mucosal antibody profiles vary geographically, and a proportion of rural Ugandan breastfeeding mothers who have not been exposed to SARS-CoV-2 have pre-existing HCoV-induced cross-reactive IgA antibodies. It is not clear if these cross-reactive IgA antibodies protect against or increase the risk of COVID-19 illness in rural mothers and their infants.

EO and GA in Uganda and AF and CD in the US contributed equally. EO, GA, TJO, AF and CD played a critical role in the acquisition of data. TGE acquired funding, designed, conceived and supervised the study in Uganda, analyzed and interpreted the data, and drafted and revised the manuscript for intellectual content. RLP acquired funding, designed, conceived and supervised the study in the US, analyzed and interpreted the data, and drafted and revised the manuscript for intellectual content. All authors approved the publication.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The data underlying this article will be shared on reasonable request to the corresponding authors.

Data suppression rules apply to ensure the anonymity of the study participants.

This work was supported by Grand Challenges Canada and Global Innovation Fund grant 0817-05 (to T.G.E.) and by the Icahn School of Medicine at Mount Sinai (to R.P.). The funders played no role in the study design, data collection and analysis, and manuscript preparation, and decision to publish.

We thank the mothers of Abwokodia Parish, Osuk subcounty in Uganda, and NYC who provided milk samples and made this study possible. 

A serological assay to detect SARS-CoV-2 seroconversion in humans

Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection

Further Evidence for Bats as the Evolutionary Source of Middle East Respiratory Syndrome Coronavirus

The mucosal immune system and its integration with the mammary glands

Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection

Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19

mRNA Vaccines in Pregnant and Lactating Women

Previous viral symptoms and individual mothers influenced the leveled duration of human milk antibodies cross-reactive to S1 and S2 subunits from SARS-CoV-2, HCoV-229E, and HCoV-OC43

Difference in levels of SARS-CoV-2 S1 and S2 subunits-and nucleocapsid protein-reactive SIgM/IgM, IgG and SIgA/IgA antibodies in human milk

Covid-19: Do many people have pre-existing immunity?

Robust and Specific Secretory IgA Against SARS-CoV-2 Detected in Human Milk

The spike-specific IgA in milk commonly-elicited after SARS-Cov-2 infection is concurrent with a robust secretory antibody response, exhibits neutralization potency strongly correlated with IgA binding, and is highly durable over time

On the Doctrine of Original Antigenic Sin

Health care worker seromonitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration

COVID-19 vaccine response in pregnant and lactating women: a cohort study

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

The potential danger of suboptimal antibody responses in COVID-19

Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2

Mother's Milk: A Purposeful Contribution to the Development of the Infant Microbiota and Immunity

Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season

Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses

Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever

An indispensable role for the chemokine receptor CCR10 in IgA antibody-secreting cell accumulation

Seroprevalence of human coronaviruses among patients visiting hospital-based sentinel sites in Uganda

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit

A Longitudinal Study of the Epidemiology of Seasonal Coronaviruses in an African Birth Cohort

Using the ultrasensitive Alere Plasmodium falciparum Malaria Ag HRP-2 ™ Rapid Diagnostic Test in the field and clinic in Northeastern Uganda

Seroepidemiology of human coronaviruses in three rural communities in Ghana

Characterization of SARS-CoV-2 RNA, Antibodies, and Neutralizing Capacity in Milk Produced by Women with COVID-19. mBio

SARS-CoV-2-Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women

Mucosal immunity in COVID-19: a neglected but critical aspect of SARS-CoV-2 infection

Recent endemic coronavirus infection is associated with less-severe COVID-19

Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63

Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity

Molecular characterization of human coronaviruses and their circulation dynamics in Kenya

Comparison of maternal milk (breastmilk) expression methods in an African nursery

Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Surveillance of Bat Coronaviruses in Kenya Identifies Relatives of Human Coronaviruses NL63 and 229E and Their Recombination History

High prevalence of preexisting serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa

Human coronaviruses: what do they cause? Antivir Ther

Acceptability of COVID-19 Vaccine in Africa

Severe COVID-19 patients display a back boost of seasonal coronavirus-specific antibodies

World Health Organization Coronavirus Disease (COVID-19) Dashboard. Accessed 18

CCR10 and its ligands in regulation of epithelial immunity and diseases

SARS-CoV-2 genome and antibodies in breastmilk: a systematic review and meta-analysis